Insuman Comb 15 Solostar

Insulin human, the active ingredient in Insuman Comb 15 Solostar, is a short‑acting insulin presented as a pre‑filled injection pen for subcutaneous administration. It is used to control blood glucose levels in adults and children with type 1 diabetes mellitus and type 2 diabetes mellitus, providing rapid onset of action after injection.

GNH USA supplies Insuman Comb 15 Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other regulated markets. The company ensures product quality through strict regulatory compliance and cold‑chain logistics.

Insuman Comb 15 Solostar, a human insulin formulation, is used in the management of diabetes mellitus by providing rapid glucose control. - Type 1 diabetes mellitus: lowers fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus: improves glycaemic control when combined with diet, exercise, or other antidiabetic agents. - Gestational diabetes mellitus: assists in achieving target glucose levels during pregnancy.

Insuman Comb 15 Solostar may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hypoglycemia: sweating, tremor, dizziness, or confusion that may require carbohydrate intake. - Injection site reactions: redness, swelling, itching, or mild pain at the injection site. - Weight gain: modest increase in body weight due to improved glucose utilization and anabolic effects.

Serious or Rare Side Effects: - Severe hypoglycemia: loss of consciousness, seizures, or need for emergency assistance. - Allergic reactions: urticaria, angioedema, or anaphylaxis that may require immediate medical treatment. - Lipodystrophy: localized fat loss or accumulation at injection sites, potentially affecting insulin absorption.

When using Insuman Comb 15 Solostar, several precautions should be observed to ensure safety and efficacy. - Dose adjustment: tailor insulin dose based on blood glucose monitoring and carbohydrate intake. - Renal impairment: monitor closely as reduced clearance may increase hypoglycemia risk. - Hepatic dysfunction: use with caution; altered insulin metabolism may occur. - Pregnancy: insulin is category B, but dosing should be individualized by a healthcare professional. - Concomitant medications: assess for agents that may potentiate hypoglycemia, such as sulfonylureas. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the pen.

Insuman Comb 15 Solostar can interact with other medicines, affecting glucose control or insulin action.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycemia symptoms. - MAO inhibitors: can potentiate insulin’s glucose‑lowering effect. - Corticosteroids: may cause significant hyperglycemia requiring dose increase.

Moderate Interactions (Monitor Closely): - Sulfonylureas or meglitinides: additive risk of hypoglycemia. - ACE inhibitors: may enhance insulin sensitivity. - Thiazide diuretics: can raise blood glucose levels. - Oral contraceptives: may slightly increase insulin requirements.